Tom Silver (@tomsilver39) 's Twitter Profile
Tom Silver

@tomsilver39

A Ω Wealth, Finance T≈Not investment/financial advice.

ID: 1330741110

calendar_today06-04-2013 05:19:47

7,7K Tweet

8,8K Takipçi

56 Takip Edilen

Tom Silver (@tomsilver39) 's Twitter Profile Photo

Oppenheimer:" We initiate Axsome Therapeutics $AXSM with an Outperform rating and $185 PT. We view AXSM as a uniquely attractive mid-cap biopharma company in neuroscience, based on multiple differentiating advantages: 1) accelerating revenue growth with three approved products

Tom Silver (@tomsilver39) 's Twitter Profile Photo

Piper:" $CYTK Takeaways from Our Investor Headquarters Visit in San Francisco...We hosted a group of investors for a headquarters visit and tour at CYTK's San Francisco office, diving into details ahead of aficamten's December 26, 2025 oHCM PDUFA. Ultimately, mgmt believes

Tom Silver (@tomsilver39) 's Twitter Profile Photo

Leerink:" Biotech Mid-Year Outlook: Top Picks $ATYR and $SYRE; Also Like $KYMR and $ZURA ... ATYR: "Not without risk" is an understatement, but we like the risk/reward setup into this Ph 3 binary in 3Q. SYRE: We think the company's focus on biologics-based combinations in IBD is

Bloomberg (@business) 's Twitter Profile Photo

Gold rose toward a record on Monday, as Israel signaled no letup in its campaign to destroy Iran’s nuclear capabilities bloomberg.com/news/articles/…

Tom Silver (@tomsilver39) 's Twitter Profile Photo

Live Updates: Israel Launches New Attacks on Iran as Conflict Enters Fourth Day #IsraelIranWar nytimes.com/live/2025/06/1…

Tom Silver (@tomsilver39) 's Twitter Profile Photo

WF:" $ABBV/ $AMGN/ $BIIB/ $BMY/ $GILD/ $MRK/ $PFE: Refreshing Our View of Potential M&A Across the SMid-Cap Landscape Smaller deals (<$5B) are more likely in 2025.... $MYLS, $TVTX, $VERA, $XENE; $AXSM; $CLDX, $IMVT, $NRIX, $RYTM, $VRDN ; $CRSP, $IOVA, $RNA, $BEAM, $TSHA ;

WF:" $ABBV/ $AMGN/ $BIIB/ $BMY/ $GILD/ $MRK/ $PFE: Refreshing Our View of Potential M&amp;A Across the SMid-Cap Landscape
Smaller deals (&lt;$5B) are more likely in 2025.... $MYLS, $TVTX, $VERA, $XENE;  $AXSM; $CLDX, $IMVT, $NRIX, $RYTM, $VRDN ; $CRSP, $IOVA, $RNA, $BEAM, $TSHA ;
Tom Silver (@tomsilver39) 's Twitter Profile Photo

Truist:" $VKTX Ph3 VANQUISH Started. GLP/GIP Dual Agonist Continue To Reign Supreme & VK2735 Could Be 2nd To Mkt; VKTX announced the start of Ph3 VANQUISH Trials for VK2735 in obesity. Obesity space has become hypercompetitive making it difficult to parse the dense efficacy and

Clint Jarvis (@clinjar) 's Twitter Profile Photo

Stanford paid 35,000 people to quit social media. This was the largest study on emotional health in history. The results were so shocking, scientists called it "comparable to therapy." Here's what happens when you break free from the algorithm: 🧵

Stanford paid 35,000 people to quit social media.

This was the largest study on emotional health in history.

The results were so shocking, scientists called it "comparable to therapy."

Here's what happens when you break free from the algorithm:
 🧵
Tom Silver (@tomsilver39) 's Twitter Profile Photo

GS:" 1) $PTGX conference call and webcast to announce oral obesity candidate and preclinical PoC on 6/30; 2) $MLTX Ph. 3 HS VELA topline results for SLK in September; 3) $VRDN Ph. 1 IgG PoC data for VRDN-006 from healthy volunteers in 3Q25..."

Tom Silver (@tomsilver39) 's Twitter Profile Photo

Cowen:" TD COWEN'S BIOTECH THERMOMETER: Sentiment toward biotech stocks improved through the month of June and enters H2 above the nadir reached earlier in the Spring..." $AGIO $BBIO $BMRN $QURE $RARE $ZYME $RVMD $IONS

Cowen:" TD COWEN'S BIOTECH THERMOMETER: Sentiment toward biotech stocks improved through the month of June and enters H2 above the nadir reached earlier in the Spring..." $AGIO $BBIO $BMRN $QURE $RARE $ZYME $RVMD $IONS
Tom Silver (@tomsilver39) 's Twitter Profile Photo

Leerink:" Biopharma Cash Runway Map: Bottom Line: Amid significant macroeconomic challenges for the Biopharma sector, we update our cash runway map for "not-yetprofitable" companies across the Leerink Partners' Biopharma Coverage Universe. The map highlights value (with >2 years

Leerink:" Biopharma Cash Runway Map: Bottom Line: Amid significant macroeconomic challenges for the
Biopharma sector, we update our cash runway map for "not-yetprofitable"
companies across the Leerink Partners' Biopharma
Coverage Universe. The map highlights
value (with &gt;2 years
Tom Silver (@tomsilver39) 's Twitter Profile Photo

Guggenheim:" $TVTX/ $VERA: Holiday Shopping in the Renal Department; TVTX and VERA Provide Derisked Opportunities at Discounted Valuations; We reiterate our Buy ratings and maintain our $47 price target for TVTX and $56 price target for VERA...."